Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: Teneligliptin (Brand name: Tenilia), an anti-hyperglycemic medication used in the treatment of TIIDM, decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 21/February/2019, 12.09 am